WO2023178111A3 - Composés organiques - Google Patents

Composés organiques Download PDF

Info

Publication number
WO2023178111A3
WO2023178111A3 PCT/US2023/064347 US2023064347W WO2023178111A3 WO 2023178111 A3 WO2023178111 A3 WO 2023178111A3 US 2023064347 W US2023064347 W US 2023064347W WO 2023178111 A3 WO2023178111 A3 WO 2023178111A3
Authority
WO
WIPO (PCT)
Prior art keywords
organic compounds
receptor
involving
carboline
dopamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/064347
Other languages
English (en)
Other versions
WO2023178111A2 (fr
Inventor
Peng Li
Robert E. Davis
Gretchen Snyder
Allen A. FIENBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Priority to EP23771593.3A priority Critical patent/EP4493560A4/fr
Priority to JP2024554790A priority patent/JP2025509569A/ja
Priority to US18/847,121 priority patent/US20250101029A1/en
Publication of WO2023178111A2 publication Critical patent/WO2023178111A2/fr
Publication of WO2023178111A3 publication Critical patent/WO2023178111A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un énantiomère particulier d'une gamma-carboline fusionnée à hétérocycle substitué, sous forme libre, solide, pharmaceutiquement acceptable et/ou sensiblement pure telle que décrite dans la description, des compositions pharmaceutiques de celle-ci, et des méthodes d'utilisation dans le traitement de maladies impliquant le récepteur 5-HT2A , et des voies impliquant le système de signalisation des récepteurs de dopamine D1 et D2.
PCT/US2023/064347 2022-03-14 2023-03-14 Composés organiques Ceased WO2023178111A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP23771593.3A EP4493560A4 (fr) 2022-03-14 2023-03-14 Composés organiques
JP2024554790A JP2025509569A (ja) 2022-03-14 2023-03-14 有機化合物
US18/847,121 US20250101029A1 (en) 2022-03-14 2023-03-14 Organic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269304P 2022-03-14 2022-03-14
US63/269,304 2022-03-14

Publications (2)

Publication Number Publication Date
WO2023178111A2 WO2023178111A2 (fr) 2023-09-21
WO2023178111A3 true WO2023178111A3 (fr) 2023-10-19

Family

ID=88024361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/064347 Ceased WO2023178111A2 (fr) 2022-03-14 2023-03-14 Composés organiques

Country Status (4)

Country Link
US (1) US20250101029A1 (fr)
EP (1) EP4493560A4 (fr)
JP (1) JP2025509569A (fr)
WO (1) WO2023178111A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
MX2024004725A (es) * 2021-10-19 2024-05-10 Intra Cellular Therapies Inc Metodos novedosos.
WO2025257090A1 (fr) 2024-06-10 2025-12-18 Interquim, S.A. Procédé de préparation d'intermédiaires de synthèse de lumatépérone et d'analogues de lumatépérone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178362A1 (en) * 1999-06-15 2006-08-10 Robichaud Albert J Substituted heterocyle fused gamma-carbolines
US20080262019A1 (en) * 2005-09-12 2008-10-23 Ramiz Medzhidovich Salimov Optical Isomers of (+) and (-)-Trans-2,3,4,4A,5,9B-Hexahydro-2,8-Dimethyl-1H-Pyrido[4,3-B] Indole
US20110046368A1 (en) * 2006-11-16 2011-02-24 Andrey Alexandrovich Ivashchenko Ligands of 5-ht6 receptors, a pharmaceutical composition, method for the production and use thereof
US20220056031A1 (en) * 2018-12-21 2022-02-24 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658144B1 (fr) * 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Composés pyridopyrroloquinoxalines, leurs compositions et utilisations en thérapie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178362A1 (en) * 1999-06-15 2006-08-10 Robichaud Albert J Substituted heterocyle fused gamma-carbolines
US20080262019A1 (en) * 2005-09-12 2008-10-23 Ramiz Medzhidovich Salimov Optical Isomers of (+) and (-)-Trans-2,3,4,4A,5,9B-Hexahydro-2,8-Dimethyl-1H-Pyrido[4,3-B] Indole
US20110046368A1 (en) * 2006-11-16 2011-02-24 Andrey Alexandrovich Ivashchenko Ligands of 5-ht6 receptors, a pharmaceutical composition, method for the production and use thereof
US20220056031A1 (en) * 2018-12-21 2022-02-24 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
US20250101029A1 (en) 2025-03-27
JP2025509569A (ja) 2025-04-11
EP4493560A2 (fr) 2025-01-22
WO2023178111A2 (fr) 2023-09-21
EP4493560A4 (fr) 2026-03-18

Similar Documents

Publication Publication Date Title
WO2023178111A3 (fr) Composés organiques
MX2020000967A (es) Compuestos organicos.
MX2020009929A (es) Compuestos organicos.
WO2023178113A3 (fr) Composés organiques
MX2021007217A (es) Compuesto organico.
MX2012012277A (es) Compuestos organicos.
WO2008046087A3 (fr) Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
WO2011106729A3 (fr) Compositions pharmaceutiques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques.
TNSN07384A1 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
EP2178869A4 (fr) Composés d'indole en tant qu'inhibiteurs de nécrose cellulaire
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
WO2008046084A3 (fr) Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
IL270395B (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
WO2024028458A3 (fr) Agonistes du récepteur muscarinique
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
WO2019175799A3 (fr) Procédé de modulation de voies de signalisation de tigit et pd-1 à l'aide de composés 1,2,4-oxadiazole
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
UA107702C2 (xx) Похідні бензаміду
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
JP2019516791A5 (fr)
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
WO2008039894A3 (fr) Compositions pharmaceutiques d'atorvastatine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771593

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024554790

Country of ref document: JP

Ref document number: 18847121

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2023771593

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023771593

Country of ref document: EP

Effective date: 20241014

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771593

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 18847121

Country of ref document: US